ADVA
19.5.2020 09:02:13 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that dacoso is using its cloud-native security solution, ConnectGuard™ Cloud, to offer secure managed services. The virtualized encryption technology will give dacoso’s customers comprehensive data protection in cloud environments. With unprecedented scale and efficiency, dacoso will be able to roll out secure connectivity within minutes, safeguarding private, public, and edge/branch clouds at Layers 2, 3 and 4. Managed centrally in dacoso’s network by ADVA’s Ensemble Controller , the VPN services offer a major boost to the region’s businesses as they look to reduce costs and enhance flexibility by migrating more of their data and applications to the cloud. Now dacoso’s enterprise customers can harness the latest cloud tools while ensuring data integrity, regulatory compliance and true peace of mind for their end users.
“We’re excited to be offering our customers the comprehensive protection of ADVA’s ConnectGuard™ Cloud technology. For many of them, total cloud security is key to their business needs. By providing strong and flexible data protection in virtual environments, we’re enabling our customers to realize their full potential by accessing cloud applications with complete peace of mind,” said Karsten Geise, head of business and product development, dacoso. “We’re convinced by the robust security and performance benefits of ConnectGuard Cloud™. So much so that we’re already harnessing the solutions to protect our own branch and cloud locations. We understand its power to protect mission-critical data while also reducing costs and enhancing network utilization.”
Implemented entirely in software, ADVA’s ConnectGuard™ Cloud is a highly scalable, standards-compliant encryption solution that provides hybrid and multi-cloud environments with the ultimate defense against cyber threats. It enables dacoso to offer its customers high-performance, transport-layer-independent security with none of the performance issues of IPSec-based technologies. As a far more efficient and cost-effective alternative to hardware security appliances, ConnectGuard™ Cloud empowers dacoso’s customers to extend encryption to remote workers and branch offices by leveraging low-cost uCPE platforms. What’s more, with zero-touch provisioning, dacoso can roll out fully secured cloud connectivity almost instantly without any manual configuration.
“Our partnership with dacoso is great news for a huge number of enterprises across this region who are currently undergoing their digital transformation. With more and more of dacoso’s customers moving their workloads to cloud environments, our ConnectGuard™ Cloud technology provides the ideal way to ensure privacy and data integrity while keeping cost and complexity low,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “As a virtualized encryption solution with zero-touch provisioning and automated key management, our ConnectGuard™ Cloud is the most readily scalable option available. It improves operational simplicity and latency performance compared to appliance-based encryption methods. What’s more, it keeps latency at its lowest levels – a key requirement for many emerging cloud applications.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About dacoso
dacoso offers solutions for Connectivity, Virtual Networking and Cyber Security. The IT service provider thereby addresses companies that need their data to be highly available and secure yet without sacrificing agility. dacoso’s services comprise, among other, optical data links encrypted to satisfy BSI requirements (Federal Office for Information Security), a certified Security Operations Center, Managed Security Services and virtualization solutions to increase the dynamic performance of networks. dacoso GmbH is an owner-managed company headquartered in Langen near Frankfurt a.M. with a further 11 locations in Germany, Austria and Switzerland. www.dacoso.com
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005058/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom